|Mr. Rostislav Raykov||CEO & Director||468.45k||N/A||1976|
|Mr. Robert C. Andrade||Chief Financial Officer||339.41k||N/A||1975|
|Mr. Mark Gowland||Controller||N/A||N/A||N/A|
|Mr. Lei Fang||Pres of Pharstat Inc||N/A||N/A||N/A|
|Ms. Anne McKay||Regulatory Consultant||N/A||N/A||1954|
|Mr. Alexander D. Smith M.S.||Consultant||N/A||N/A||N/A|
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc.’s ISS Governance QualityScore as of May 1, 2022 is 6. The pillar scores are Audit: 9; Board: 5; Shareholder Rights: 5; Compensation: 8.